Funding for this research was provided by:
AstraZeneca
Article History
Accepted: 1 February 2021
First Online: 12 March 2021
Declarations
:
: Medical writing support, under the direction of the authors, was provided on the manuscript outline by Jacqueline Kolston PhD, Mudskipper Business Ltd, Macclesfield, UK, and on subsequent drafts by Michael Riley PhD, Oxford PharmaGenesis Ltd, Cardiff, UK. Medical writing support was funded by AstraZeneca, Cambridge, UK, in accordance with Good Publication Practice 3 guidelines.
: Laura Cortesi reports honoraria from AstraZeneca, Merck Sharp & Dohme, and Pfizer, and consultancy for Pfizer, Novartis, Tesaro, and Clovis. Hope S. Rugo reports research support to the University of California San Francisco from Pfizer, Merck, Novartis, Lilly, Macrogenics, Roche, OBI, Odonate, Eisai, and Daichi, as well as travel support from Pfizer, Novartis, Roche, and Mylan. Christian Jackisch has received honoraria from Amgen, Celgene, Lilly, Novartis, Pfizer, AstraZeneca, and Roche, and research support from Genomic Health.
: All authors contributed to the conception, design and drafting of the manuscript; all authors critically reviewed the manuscript and approved the final submitted version.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.